A biomarker is, according to the US National Institutes of Health, “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.”
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
We can discriminate four main types of molecular biomarkers:
• Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
• Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.
• Proteomic biomarkers: Base on the analysis of the protein profiles.
• Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).

Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
This report contains market size and forecasts of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Global, including the following market information:
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market was valued at 22010 million in 2021 and is projected to reach US$ 30140 million by 2028, at a CAGR of 4.6% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Consumables Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications include Roche, Dako (Agilent Technologies), Merck, BD, Abbott, Genesys Biolabs (20/20GeneSystems), Affymetrix, Agendia and ALMAC, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Commercializing Biomarkers in Therapeutic and Diagnostic Applications companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Segment Percentages, by Type, 2021 (%)
Consumables
Services
Software
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Segment Percentages, by Application, 2021 (%)
Oncology
Cardiology
Neurology
Other
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Commercializing Biomarkers in Therapeutic and Diagnostic Applications revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Commercializing Biomarkers in Therapeutic and Diagnostic Applications revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI